Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four active pharmaceutical ingredients: - **Caffeine** is a central nervous system stimulant commonly used to increase alertness and reduce fatigue. It acts primarily as an adenosine receptor antagonist. - **Losartan** is an angiotensin II receptor blocker (ARB) used mainly for the treatment of hypertension and to protect the kidneys from damage due to diabetes. It works by blocking the action of angiotensin II, resulting in vasodilation. - **Midazolam** is a short-acting benzodiazepine with anxiolytic, amnestic, hypnotic, anticonvulsant, and muscle relaxant properties. It acts as a positive allosteric modulator at GABA-A receptors. - **Omeprazole** is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the H^+/K^+-ATPase enzyme system in gastric parietal cells[2][4][5][6][8]. There are no known approved pharmaceutical products or brand names containing this exact combination; it appears to be an investigational or research-use-only mixture rather than a marketed drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + losartan + midazolam + omeprazole.